newsfilter
← Latest News
PR Newswire·

Sobi to license loncastuximab tesirine from ADC Therapeutics

Agreement augments Sobi's strategic presence in haematology with new orphan medicine STOCKHOLM, July 8, 2022 /PRNewswire/ -- Sobi® today announced an exclusive license agreement with ADC Therapeutics SA to develop and commercialise loncastuximab tesi